Related Experiment Videos
[A case of agammaglobulinemia with chronic progressive encephalopathy]
Insights
This study details a young man with X-linked agammaglobulinemia who developed chronic progressive encephalopathy. Further molecular research is needed to determine the cause of this neurological decline.
Area of Science:
- Immunology
- Neurology
- Genetics
Background:
- X-linked agammaglobulinemia (XLA) is a primary immunodeficiency characterized by a severe lack of B cells and antibodies.
- Patients with XLA are susceptible to recurrent bacterial infections, but neurological complications are less common.
- Chronic progressive encephalopathy is a severe neurological disorder with significant morbidity and mortality.
Observation:
- A 21-year-old male with a history of XLA presented with progressive neurological decline starting at age 11.
- Clinical manifestations included declining school performance, personality changes, seizures, myoclonus, spasticity, and loss of motor and speech functions.
- Neuroimaging revealed diffuse cerebral atrophy, with relative preservation of the cerebellum and brainstem.
Findings:
- Viral studies and antibody titers for common infections were negative, ruling out typical infectious causes.
- The patient's neurological symptoms and imaging findings suggest a non-infectious encephalopathy.
- The progressive nature of the encephalopathy in the context of agammaglobulinemia raises suspicion for a potential complication of the underlying condition.
Implications:
- This case highlights a rare but severe neurological complication associated with X-linked agammaglobulinemia.
- The findings suggest that chronic progressive encephalopathy may be an under-recognized manifestation in patients with primary immunodeficiencies.
- Further investigation using advanced molecular techniques is crucial to elucidate the etiology and pathogenesis of this neurological disorder.
Abstract:
We report a 21-year-old man with agammaglobulinemia and chronic progressive encephalopathy. The patient was diagnosed as having X-linked agammaglobulinemia at 6 months of age, and gamma globulin supplementation was initiated. He exhibited normal development until he was 11 years old, when he showed a decline in school performance and a personality change. Computed tomography images at that time disclosed diffuse cerebral atrophy. Several generalized tonic-clonic convulsions, myoclonus and spasticity appeared at the age of 13 years. He lost his ability to walk and speak at the age of 17 years old. He is currently 21 years old and displays severe mental deterioration and spastic tetraplegia. Magnetic resonance imaging showed progressive diffuse cerebral atrophy with no change in intensity. The cerebellum and the brain stem were relatively well maintained. Viral isolations were negative and serum antibody titers for rubella, measles, and human immune deficiency virus were not elevated. Our patient's symptoms resemble those previously reported as chronic progressive encephalopathy without viral isolation. This condition may be a complication of agammaglobulinemia. It is possible that the encephalopathy of our patient has the same etiology as that described in the other reports. Further attempts to identify the etiology of the encephalopathy using molecular techniques are necessary.